Majority Of Wyeth Growth Pegged To Licensed Biotech Products, Execs Say
Half of big pharma’s developmental pipeline should come from outside innovators, Wyeth BioPharma’s Redmund says.
Half of big pharma’s developmental pipeline should come from outside innovators, Wyeth BioPharma’s Redmund says.